NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES

BASEL, Switzerland, Sept. 28 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) discloses its list of licenses.

NEURO # 1

SymPath(R)

TO EVALUATE THE SYMPATHETIC NERVOUS SYSTEM THROUGH THE ENZYME, DOPAMINE Beta- HYDROXYLASE (DBH), THAT IS RELEASED WITH NORADRENALINE WITHIN THE BLOOD AND DISTINGUISH BETWEEN DEPRESSIVE STATES AND ANXIOUS DISORDERS.

NEURO # 2

AXIS(TM)

TO QUANTITATIVELY AND DIRECTLY EVALUATE THE HYPOTHALAMO-PITUITARY ADRENAL AXIS THROUGH ENDING MOLECULES FORMED FROM THE RELEASED ACTH WITHIN THE BLOOD AND ACTING ON DESMOLASE ENZYME ACTIVITY, REQUIRING CHOLESTEROL BIOAVAILABILITY.

NEURO # 3

TETRIC(TM)

TO UNDERSTAND THE RELATIONSHIP BETWEEN CONSTITUTIVE & INDUCTIVE DBH ENZYME IN ORDER TO DISCRIMINATE PSYCHOAFFECTIVE AND MENTAL DISTURBANCES, THROUGH SIEVING MOLECULAR WEIGHT.

NEURO #4 and #5

ARE ONE PLATFORM FOR ALL OF THEM: 5-HT / 5HIAA DA / DOPAC / HVA NA / VMA / A MELATONIN TO UNDERSTAND THE RELATIONSHIP BETWEEN NEUROTRANSMITTERS, THE TURNOVER OF THEIR METABOLITES, AND TO FIGURE OUT THE CLINICAL PREDOMINENCE

NEURO # 6

TRYPTYR

TO EVALUATE THE BIOAVAILIBILITY OF TWO MAIN NEURO-TRANSMITTERS SUBSTRATES AND THEIR IMPACT IN BRAIN 5-HT AND NA SYNTHESIS.

NEURO #7

DIVAN

TO EVALUATE THE BIOAVAILABILITY OF THE EIGHT (8) ELECTROLYTES AND THEIR RELATIONSHIPS INVOLVED IN THE CNS.

NEURO # 8

GACHA

TO EVALUATE THE GABA AND ACETHYLCHOLINE RELATIONSHIP AT THE CELLULAR ENERGETIC CAPACITY.

NEURO # 9

FREERAD

TO MEASURE THE FREE RADICALS AND DETERMINE THEIR PREDOMINANCE IN REGARDS TO THE AXIS ACTIVITY.

NEURO # 10

MAOS

TO DETERMINE THE MAO TYPE A OR B ACTIVITY AND TO DEFINE THE CLINICAL PATIENT PROFILE IN RESPECT TO EXPECTED DIAGNOSIS AND THERAPEUTIC APPROACHES.

NEURO # 11

NEURENDOM

TO DEFINE THE MALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.

NEURO # 12

NEURENDOF

TO DEFINE THE FEMALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.

SOURCE Neuro-Biotech Corp.

Copyright . 28 PR Newswire